No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with extended-interval dosing (EID) in patients with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: We switched NZ dosing from 4-week to 6-week intervals in patients with RRMS, and investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnsson, Magnus, Farman, Helen H, Blennow, Kaj, Zetterberg, Henrik, Malmeström, Clas, Axelsson, Markus, Lycke, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574231/
https://www.ncbi.nlm.nih.gov/pubmed/35856574
http://dx.doi.org/10.1177/13524585221108080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574231/
https://www.ncbi.nlm.nih.gov/pubmed/35856574
http://dx.doi.org/10.1177/13524585221108080

Ejemplares similares